Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer

BACKGROUND: We have recently described the correlation between quantitative measures of HER2 expression or HER2 homodimers by the HERmark assay and objective response (RR), time-to progression (TTP), and overall survival (OS) in an expanded access cohort of trastuzumab-treated HER2-positive patients...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Toi, Masakazu, Sperinde, Jeff, Huang, Weidong, Saji, Shigehira, Winslow, John, Jin, Xueguang, Tan, Yuping, Ohno, Shinji, Nakamura, Seigo, Iwata, Hiroji, Masuda, Norikazu, Aogi, Kenjiro, Morita, Satoshi, Petropoulos, Christos, Bates, Michael
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2010
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2837013/
https://ncbi.nlm.nih.gov/pubmed/20178580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-10-56
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares